Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
This study collects and stores tissue samples and medical information from patients with age-related macular degeneration. These biospecimens and data are then made available to researchers who have been approved by institutions to conduct studies aimed at finding new treatments, diagnostics, and prevention methods for this and other conditions.
Key Objective: The potential benefit is contributing to the discovery and development of new treatments and diagnostic tools for age-related macular degeneration and other diseases.
Who to Consider: Patients with age-related macular degeneration who are willing to donate tissue samples and have their medical information used for approved research studies should consider enrolling.
Trial Parameters
Brief Summary
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Eligibility Criteria
Inclusion Criteria: * Persons 18 to 85 years of age at the date of informed consent. * If presenting with a history of a specific condition, the diagnosis is confirmable in the medical record or may be confirmed using other forms of verification including self-reporting. * Understands the procedures and requirements of the study by providing written informed consent (or verbal assent if a legally authorized representative will sign the ICF), including consent for authorization for protected health information disclosure. Exclusion Criteria: * Persons younger than 18 years of age or older than 85 years of age at the date of informed consent. * Receipt of blood products 30 days before the study blood draw. * Receipt of an investigational (unapproved) drug 30 days before the study blood draw. * A confirmable diagnosis of any medical condition that would increase potential phlebotomy risks. * Has donated a unit of blood within the last 2 months at the date of informed consent.